TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21252208

Group type: EXPERIMENTAL
Intervention: Minimized bypass circuit (Group A)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard bypass circuit (Group B)
Number of subjects: 80
Study: 18922086

Group type: EXPERIMENTAL
Intervention: pVIS light (385-750 nm)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: pVIS + nIR light (385-1700 nm)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (no light exposure)
Number of subjects: 50
Study: 17333787

Group type: EXPERIMENTAL
Intervention: Prednisolone, 30 mg/day for 10 days
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Paracentesis to remove fluid
Number of subjects: 190

Group type: COMPARATOR
Intervention: Anti-tuberculosis (TB) drugs for 6 months
Number of subjects: 190
Study: 15125487

Group type: EXPERIMENTAL
Intervention: Alcohol (one ounce, corresponding to two drink equivalents)
Number of subjects: 12
Study: 10929163

Group type: EXPERIMENTAL
Intervention: Zinc acetate lozenges (12.8 mg)
Number of subjects: 50
Study: 8931165

Group type: EXPERIMENTAL
Intervention: D-fenfluramine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 1396796

Group type: EXPERIMENTAL
Intervention: Omnipaque (iohexol) 350 mgI/ml
Number of subjects: 60

Group type: COMPARATOR
Intervention: Telebrix (sodium-meglumine-ioxithalamate) 350 mgI/ml
Number of subjects: 60
Study: 2861365

Group type: EXPERIMENTAL
Intervention: Biodegradable polylactide‐glycolide copolymer implants
Number of subjects: 44

Group type: COMPARATOR
Intervention: Conventional metallic implants
Number of subjects: 44
Study: 30712718

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 28
Study: 28820746

Group type: EXPERIMENTAL
Intervention: D-Cycloserine (125 mg) administered pre-exposure therapy
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: D-Cycloserine (125 mg) administered post-exposure therapy
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 25403903

Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg subcutaneously every 6 months for 3 years
Number of subjects: 810

Group type: COMPARATOR
Intervention: Denosumab 60 mg subcutaneously every 6 months for 1 year (cross-over group)
Number of subjects: 810
Study: 24771706

Group type: EXPERIMENTAL
Intervention: Wrist self-monitoring device with daily BP measurement for 24 weeks
Number of subjects: 196

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Wrist self-monitoring device
Number of subjects: 196

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 196
Study: 21786110

Group type: EXPERIMENTAL
Intervention: MV-CBCT (megavolt cone-beam CT)
Number of subjects: 9

Group type: COMPARATOR
Intervention: MV-CBCT (automatic registration)
Number of subjects: 9

Group type: COMPARATOR
Intervention: MV-CBCT (soft tissue registration)
Number of subjects: 9
Study: 19366127

Group type: EXPERIMENTAL
Intervention: CPC loading rhBMP-2
Number of subjects: 112

Group type: COMPARATOR
Intervention: CPC
Number of subjects: 112
Study: 17695700

Group type: EXPERIMENTAL
Intervention: Angiotensin II receptor blockers (ARBs)
Number of subjects: 0
Study: 14769778

Group type: EXPERIMENTAL
Intervention: 5 mg 5‐MTHF
Number of subjects: 0

Group type: COMPARATOR
Intervention: 5 mg folic acid
Number of subjects: 0
Study: 12365087

Group type: EXPERIMENTAL
Intervention: Single treatment (ACE inhibitor, beta‐blocking drug or ARB)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Single treatment (calcium channel‐blocking drug or thiazide diuretic)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Fixed combination therapy (one drug from group 1 and one drug from group 2)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Initial monotherapy maintained alone or in combination
Number of subjects: 48
Study: 9677171

Group type: EXPERIMENTAL
Intervention: STD treatment (directly observed, single oral dose)
Number of subjects: 11618

Group type: COMPARATOR
Intervention: Control arm received anthelminthic and iron-folate (directly observed, single oral dose)
Number of subjects: 11618
Study: 7983527

Group type: EXPERIMENTAL
Intervention: Human insulin (HI)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Porcine insulin (PI)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Hypoglycemia (20 min and 50 min)
Number of subjects: 30
Study: 3142412

Group type: EXPERIMENTAL
Intervention: Copal UA-251 (Philips) self-blood pressure measurement device
Number of subjects: 38
Study: 4884653

Group type: EXPERIMENTAL
Intervention: Azathioprine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31870314

Group type: EXPERIMENTAL
Intervention: Multicomponent exercise intervention (twice a week for 16 weeks, 45-60 minutes each session)
Number of subjects: 1120

Group type: COMPARATOR
Intervention: Waiting time control group
Number of subjects: 1120
Study: 28063216

Group type: EXPERIMENTAL
Intervention: Low-energy-dense (LED) snack food
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: High-energy-dense (HED) snack food
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: High dietary restraint individuals randomized to LED food
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Baseline eating-related variables
Number of subjects: 77
Study: 25526228

Group type: COMPARATOR
Intervention: KB220Z
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 23026057

Group type: EXPERIMENTAL
Intervention: Nicotine gum (6 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 20
Study: 21789658

Group type: EXPERIMENTAL
Intervention: Burch colposuspension
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Fascial retropubic sling
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Self‐administered questionnaires
Number of subjects: 450
Study: 19690548

Group type: EXPERIMENTAL
Intervention: Gemcitabine (1000 mg m(‐2) over 30 min on days 1, 8, and 15, every 4 weeks for 3 cycles)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Surgery-only
Number of subjects: 118
Study: 16803844

Group type: EXPERIMENTAL
Intervention: S-1 alone (2 weeks of treatment and 1 week of rest for 6 months, followed by 2 weeks of treatment and 2 weeks of rest for 6 months)
Number of subjects: 280

Group type: COMPARATOR
Intervention: S-1 plus PSK (the same regimen of S-1 plus daily PSK for 12 months)
Number of subjects: 280
Study: 12717216

Group type: EXPERIMENTAL
Intervention: Sirolimus plus steroids (SRL+ST)
Number of subjects: 430

Group type: COMPARATOR
Intervention: Sirolimus with cyclosporine A plus steroids (SRL+CsA+ST)
Number of subjects: 430
Study: 15040375

Group type: EXPERIMENTAL
Intervention: Emerging areas of consensus in consent rules for paediatric research
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: UK, European, and International norms on consent rules
Number of subjects: 0
Study: 9283538

Group type: EXPERIMENTAL
Intervention: Conscious sedation with combined intravenous midazolam, morphine, and promethazine, plus deep sedation with etomidate
Number of subjects: 162

Group type: COMPARATOR
Intervention: Propofol anesthesia administered by an attending anesthesiologist
Number of subjects: 162
Study: 8517422

Group type: EXPERIMENTAL
Intervention: Preprocedural variables
Number of subjects: 1442

Group type: EXPERIMENTAL
Intervention: Postprocedural variable
Number of subjects: 1442

Group type: EXPERIMENTAL
Intervention: Preprocedural multivariate model
Number of subjects: 1442
Study: 3469057

Group type: EXPERIMENTAL
Intervention: Citalopram 40 mg/day
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Citalopram 20 mg/day
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 28982517

Group type: EXPERIMENTAL
Intervention: Preoperative biochemical markers (albumin, CRP, hemoglobin, eGFR)
Number of subjects: 2093

Group type: EXPERIMENTAL
Intervention: Categorized parameters of preoperative biochemical markers
Number of subjects: 2093

Group type: EXPERIMENTAL
Intervention: ROC curve analysis for albumin
Number of subjects: 2093

Group type: EXPERIMENTAL
Intervention: Predictive values of preoperative biochemical markers
Number of subjects: 2093
Study: 27131407

Group type: EXPERIMENTAL
Intervention: Amaranth extract (2 g as single dose)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 24884722

Group type: EXPERIMENTAL
Intervention: Access to the 'Living well with asthma' website for 12 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual asthma care for 12 weeks
Number of subjects: 0
Study: 21142821

Group type: EXPERIMENTAL
Intervention: Tablets with resinate (dextromethorphan loaded into Amberlite IRP-69 resin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tablets with physical mixture (dextromethorphan physically mixed with resin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tablets with resinate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tablets with physical mixture
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both tablets (resinate and physical mixture)
Number of subjects: 0
Study: 20337831

Group type: EXPERIMENTAL
Intervention: Physical therapy treatment
Number of subjects: 90
Study: 18545786

Group type: EXPERIMENTAL
Intervention: Lysine clonixinate (LC)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Dipyrone (metamizole)
Number of subjects: 30
Study: 15933977

Group type: EXPERIMENTAL
Intervention: Acute normovolaemic haemodilution (ANH)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Cell salvage alone
Number of subjects: 36
Study: 12856119

Group type: EXPERIMENTAL
Intervention: Intravenous teicoplanin (6 mg/kg per 12 h for 48 h, then 6 mg/kg daily)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Subcutaneous teicoplanin (30-min administration)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Subcutaneous teicoplanin
Number of subjects: 12

Group type: COMPARATOR
Intervention: Intravenous teicoplanin
Number of subjects: 12
Study: 10582392

Group type: EXPERIMENTAL
Intervention: Dinoprostone
Number of subjects: 156

Group type: COMPARATOR
Intervention: Oxytocin
Number of subjects: 156
Study: 8600201

Group type: EXPERIMENTAL
Intervention: Triazolam 0.375 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 1780722

Group type: EXPERIMENTAL
Intervention: Gallium arsenide laser treatment with standard conservative treatment
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo laser treatment with standard conservative treatment
Number of subjects: 42
Study: 6153057

Group type: EXPERIMENTAL
Intervention: Computer feedback
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Physician education program
Number of subjects: 4

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 4

Group type: COMPARATOR
Intervention: All patient groups (including control)
Number of subjects: 4
Study: 28776304

Group type: EXPERIMENTAL
Intervention: Education about oral mucositis prevention, including training and Patient Education Booklet
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Education about oral mucositis prevention
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no education)
Number of subjects: 60
Study: 28027413

Group type: EXPERIMENTAL
Intervention: Omega 3 (1 gm three times daily for 3 months)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Dexamethasone (1.5 ml) and hyaluronidase (1500 IU) mixed with lignocaine (biweekly for 6 weeks) and placebo (for 3 months)
Number of subjects: 10
Study: 26482279

Group type: EXPERIMENTAL
Intervention: Lenvatinib plus everolimus (18 mg/day and 5 mg/day)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Single-agent lenvatinib (24 mg/day)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Single-agent everolimus (10 mg/day)
Number of subjects: 153
Study: 23798465

Group type: EXPERIMENTAL
Intervention: GSTT1 null genotype
Number of subjects: 609

Group type: COMPARATOR
Intervention: Control group (non-GSTT1 null genotype)
Number of subjects: 609
Study: 22827783

Group type: EXPERIMENTAL
Intervention: Methimazole (MMI) treatment
Number of subjects: 239

Group type: COMPARATOR
Intervention: Radioiodine (RAI) treatment with thyroxine
Number of subjects: 239
Study: 18534441

Group type: EXPERIMENTAL
Intervention: Hydroxyapatite-coated femoral stems
Number of subjects: 61

Group type: COMPARATOR
Intervention: Non-hydroxyapatite-coated femoral stems
Number of subjects: 61
Study: 17700991

Group type: EXPERIMENTAL
Intervention: Clazosentan 0.2 mg/kg/h
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Clazosentan (Part B)
Number of subjects: 34
Study: 15321807

Group type: EXPERIMENTAL
Intervention: Ad libitum low-fat, high-carbohydrate diet
Number of subjects: 11

Group type: COMPARATOR
Intervention: High-monounsaturated fat diet
Number of subjects: 11
Study: 15588309

Group type: EXPERIMENTAL
Intervention: Adults with PDS
Number of subjects: 10

Group type: COMPARATOR
Intervention: Non-stutterers (controls)
Number of subjects: 10
Study: 10599904

Group type: EXPERIMENTAL
Intervention: 100 mg doxycycline daily for 14 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no doxycycline)
Number of subjects: 20
Study: 8530236

Group type: EXPERIMENTAL
Intervention: Dissecting the ureter at the initiation of laparoscopic hysterectomy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (not dissecting the ureter)
Number of subjects: 60
Study: 1785703

Group type: EXPERIMENTAL
Intervention: 10 mg diazepam
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 150 mg ranitidine
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 35 micrograms enprostil
Number of subjects: 120

Group type: COMPARATOR
Intervention: 30 ml of 0.5 M sodium citrate
Number of subjects: 120
Study: 7225999

Group type: EXPERIMENTAL
Intervention: ACM (Adriamycin, Cyclophosphamide, Methotrexate)
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: ACM-ADV (alternating ACM and ADV)
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: ADV (Actinomycin-D, DTIC, Vincristine)
Number of subjects: 232
Study: 29226778

Group type: EXPERIMENTAL
Intervention: Fatigue: Take Control (FTC)
Number of subjects: 204

Group type: COMPARATOR
Intervention: MS: Take Control (MSTC)
Number of subjects: 204
Study: 29653858

Group type: EXPERIMENTAL
Intervention: rhNGF 10 μg/ml
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: rhNGF 20 μg/ml
Number of subjects: 156

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 156
Study: 26817717

Group type: EXPERIMENTAL
Intervention: 400 μg FA/d
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study: 25175029

Group type: EXPERIMENTAL
Intervention: Tachosil® application
Number of subjects: 140

Group type: COMPARATOR
Intervention: No application (Control)
Number of subjects: 140
Study: 21812797

Group type: EXPERIMENTAL
Intervention: Orlistat 360mg
Number of subjects: 254

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 254
Study: 20817653

Group type: EXPERIMENTAL
Intervention: Physical exercise programme at the spine clinic
Number of subjects: 246

Group type: COMPARATOR
Intervention: Brief intervention programme (control)
Number of subjects: 246
Study: 17640853

Group type: EXPERIMENTAL
Intervention: CD34+ selected PBPC (arm A)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Unselected PBPC (arm B)
Number of subjects: 111
Study: 16337574

Group type: EXPERIMENTAL
Intervention: 3‐mm ancillary trocars
Number of subjects: 102

Group type: COMPARATOR
Intervention: 5‐mm ancillary trocars
Number of subjects: 102
Study: 12032038

Group type: EXPERIMENTAL
Intervention: Epidural morphine (EM; 17 mL of 2% lidocaine plus 2 mg of morphine)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: IV morphine (IVM; 17 mL of 2% lidocaine plus 0.2 mL of normal saline, followed by IVM 2 mg IV)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control (17 mL of 2% lidocaine plus 0.2 mL of normal saline, followed by 0.2 mL of normal saline IV)
Number of subjects: 45
Study: 9536191

Group type: EXPERIMENTAL
Intervention: Social support boosting intervention
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 70
Study: 8561380

Group type: EXPERIMENTAL
Intervention: Psychotherapy (long-term treatment)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Psychotherapy alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Various modalities of psychotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Psychologists, psychiatrists, and social workers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Marriage counselors and long-term family doctoring
Number of subjects: 0

Group type: COMPARATOR
Intervention: Limited therapy or choice of therapist due to insurance or managed care
Number of subjects: 0
Study: 31739848

Group type: EXPERIMENTAL
Intervention: Technology assisted sleep extension intervention (wearable sleep tracker, smartphone application, weekly didactic lessons, brief telephone coaching)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Technology assisted sleep extension intervention
Number of subjects: 16

Group type: COMPARATOR
Intervention: Self-management control group
Number of subjects: 16
Study: 29851204

Group type: EXPERIMENTAL
Intervention: Vesatolimod (1-, 2-, or 4-mg) once weekly for 12 weeks
Number of subjects: 192

Group type: COMPARATOR
Intervention: Placebo once weekly for 12 weeks
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (300-mg daily) for 48 weeks
Number of subjects: 192
Study: 29231362

Group type: EXPERIMENTAL
Intervention: Combined therapy group (scraping therapy + xuanfei zhisou decoction)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Chinese herbal medicine group (xuanfei zhisou decoction)
Number of subjects: 80
Study: 25042213

Group type: EXPERIMENTAL
Intervention: QUIT intervention of brief clinician advice and up to two drug-use health telephone sessions
Number of subjects: 334

Group type: COMPARATOR
Intervention: Usual care and information on cancer screening
Number of subjects: 334
Study: 23216897

Group type: EXPERIMENTAL
Intervention: 2-month Physical Activity (PA) intervention, involving supervised PA sessions and a behavioural change component.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (Control group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2-month Physical Activity (PA) intervention
Number of subjects: 0
Study: 19161564

Group type: EXPERIMENTAL
Intervention: Rizatriptan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 17597256

Group type: EXPERIMENTAL
Intervention: Intravenous morphine (0.1 mg/kg, maximum 5 mg)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 15585800

Group type: EXPERIMENTAL
Intervention: 1600 IU vitamin D2 and 400 IU vitamin D3
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 3600 IU vitamin D2 and 400 IU vitamin D3
Number of subjects: 18

Group type: COMPARATOR
Intervention: 400 IU/d vitamin D (control)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 2000 IU/d vitamin D
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 4000 IU/d vitamin D
Number of subjects: 18
Study: 11720695

Group type: EXPERIMENTAL
Intervention: Nortriptyline or Paroxetine (12 weeks treatment)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group (n = 16)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Nonremitters (n = 16)
Number of subjects: 76
Study: 9497787

Group type: EXPERIMENTAL
Intervention: NG-monomethyl-L-arginine, 1-4 mumol/min
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Noradrenaline, 60-240 pmol/min
Number of subjects: 40
Study: 7930694

Group type: EXPERIMENTAL
Intervention: Zidovudine therapy
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control (not treated)
Number of subjects: 64
Study: 3074298

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31347768

Group type: EXPERIMENTAL
Intervention: Tris/Arg cleanser
Number of subjects: 34

Group type: COMPARATOR
Intervention: AEC/AC-based cleanser
Number of subjects: 34
Study: 29863451

Group type: COMPARATOR
Intervention: Tamoxifen alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tamoxifen plus ovarian suppression
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exemestane plus ovarian suppression
Number of subjects: 0
Study: 28249592

Group type: EXPERIMENTAL
Intervention: Counselling for Depression (CfD)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Cognitive Behaviour Therapy (CBT)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Cost-effectiveness determined by a patient service receipt questionnaire
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Secondary outcome measures
Number of subjects: 500
Study: 23553185

Group type: EXPERIMENTAL
Intervention: Tailored intervention combining individual sessions based on motivational interviewing and group sessions
Number of subjects: 365

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 365
Study: 23782520

Group type: EXPERIMENTAL
Intervention: Individualized homeopathic treatment
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 189

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 189
Study: 20082131

Group type: EXPERIMENTAL
Intervention: MinVP
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: MinVP with AF algorithms
Number of subjects: 110

Group type: COMPARATOR
Intervention: DDDR (control)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control phase (DDDR)
Number of subjects: 110
Study: 21444270

Group type: EXPERIMENTAL
Intervention: Chlorhexidine cavity disinfectants
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mouthrinse and antiseptic (as chlorhexidine agents)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 15722805

Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 12547542

Group type: EXPERIMENTAL
Intervention: Recombinant factor VIIa 20 microg/kg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Recombinant factor VIIa 40 microg/kg
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36

Group type: COMPARATOR
Intervention: Recombinant factor VIIa vs Control
Number of subjects: 36
Study: 10373275

Group type: EXPERIMENTAL
Intervention: Greater relative right-sided activation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Greater relative left-sided activation
Number of subjects: 0